We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 2.80 | 8.24% | 36.80 | 753,383 | 16:35:27 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 36.60 | 37.30 | 37.30 | 35.00 | 35.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | -5.85M | -0.0194 | -18.81 | 109.76M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:27 | UT | 6,817 | 36.80 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 29/4/2024 | 07:00 | UK RNS | Futura Medical PLC Directors’ / PDMR Dealing and Grant of Options |
| 10/4/2024 | 10:49 | ALNC |  Futura Medical hails results as erectile dysfunction drug drives sales |
| 10/4/2024 | 07:00 | UK RNS | Futura Medical PLC Results for the Year ended 31 December 2023 |
| 25/3/2024 | 07:00 | UK RNS | Futura Medical PLC Notice of Results and Investor Presentation |
| 14/2/2024 | 09:24 | ALNC | IN BRIEF: Futura Medical's Eroxon to soon be available on prescription |
| 14/2/2024 | 07:00 | UK RNS | Futura Medical PLC Eroxon to be available on prescription |
| 06/2/2024 | 12:24 | ALNC | Futura Medical shares surge after "transformational year" |
| 06/2/2024 | 07:01 | UK RNS | Futura Medical PLC Trading Update |
| 06/2/2024 | 07:00 | UK RNS | Futura Medical PLC Appointment of Joint Corporate Broker |
| 17/1/2024 | 07:00 | UKREG | Futura Medical PLC Remuneration of Non-Exec Directors & Voting Rights |
Futura Medical (FUM) Share Charts1 Year Futura Medical Chart |
|
1 Month Futura Medical Chart |
Intraday Futura Medical Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/5/2024 | 22:42 | FUTURA a winner for 2015 | 21,069 |
| 02/3/2024 | 11:36 | FUM this ones bound to rise! | 93 |
| 31/10/2023 | 15:48 | fum value | 1 |
| 02/7/2023 | 10:15 | Quiet on here | 34 |
| 12/6/2023 | 17:18 | FUTURA - FDA Approval Due in 2023 | 4 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 04/5/2024 09:20 by Futura Medical Daily Update Futura Medical Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 34p.Futura Medical currently has 300,712,293 shares in issue. The market capitalisation of Futura Medical is £109,759,987. Futura Medical has a price to earnings ratio (PE ratio) of -18.81. This morning FUM shares opened at 35p |
Posted at 04/5/2024 17:24 by mdi And at 30 June 2023 there is also now close to £65 million in retained losses in Futura. The question is if Eroxon has been more or less fully licensed out so as the distributors control its future. And all of the other Futura products have now disappeared. Why would the large shareholders be willing to continue to pay the Directors well over £1m per year to be effectively doing nothing? Never mind the adding in of the annual costs of being AIM market listed. And if as they say they dont need to raise any more money even at this current £100m paper market valuation from shareholders. Then why even waste money on being listed? Didn’t they claim in the recent presentation Q&A they were starting to get some institutional interest? Yet the share price even with all the supposedly positive future is still falling over the last few weeks and months? |
Posted at 04/5/2024 16:53 by mdi How much has the Futura market cap declined now since June of last year? I read that the major shareholders average price is still well below even the current share price. So even even if the share price declines further they will still be in profit. So will Directors on many of their 7p and 15p share options if the share price even falls another 40% to the low 20’s. That would still be a Market Cap of nearly £70mHard to tell which is falling faster now. Eroxon sales after the hype or the Futura market cap after the hype. But the fact remains that the £1.7m revenue in April/May was followed by only £1.4m in the following 6 months. New market launches being hyped and staggered may well help short term to prop up the obvious declining sales. |
Posted at 12/4/2024 12:21 by takeiteasy Total and complete capitulation it seems...I wonder where Haleon are at with all this. They have given this project a very high profile and will manage every risk for success - mindful that durex and the rest will jump at the chance to compete at a drop of a hat if they think there is a real market out there. If I was Haleon I would take the following steps to manage risks: Wait until sufficient air cover is in place with enough patents Give no information out whatsoever on repeat purchasing - so no one can guess the market opportunity Establish sufficient manufacturing scale in USA for go live Get some follow up female products ready so it appears a product suite can be established rather than a one hit wonder Give a sense go live is a long way off to form the impression for the oppo there is no rush to bring forward rival offerings If that is the plan, FUM knows it will trash the share price as it has done so a payment has to be made to compensate near term... This is my only way of understanding what is going on - if anyone else can see the wood from the trees better - happy days :) dyor and no advice and imvho |
Posted at 08/4/2024 14:30 by z1co The slight pull back has finished , i expect the share price to rise strongly.Broomrigg , i'm sure you meant Wednesday |
Posted at 28/2/2024 11:41 by takeiteasy Today has proved my theory that the higher the price above 40p the greater the sense of panic in the camp and I see we have 3 cut and paste jobs in a row on the other thread - that are fortunately filtered.When we get the share price over 50p he will be up to post every half hour I suspect :) |
Posted at 06/2/2024 15:47 by keifer derrin Dermsys is the base product and in the early days, FUM added a drug to dermasys for ED.Unusally for the Phase III trail the authorities made FUM use dermasys as the plecebo. Normally they would have used another inert gel product When the test was released it appeared that dermasys worked the same as with the added drug. Which was it worked in 60% of males. Hence why it appears that it was the same as a placebo As they didn't need to use the added "drug" it allowed FUM to proceed down the current route without having to do any extra tests. Although the FDA made FUM do some other testing on African Americans and that it worked over a period of time. From this test FUM also found that the longer they used the product the better the erection (edited to add extra to post |
Posted at 06/2/2024 08:34 by oxford43 Sales would be £3.6m and have beaten £3.4m if the £0.5m had not been delayed to Jan. If US gets going 2024 could be a transformational year for FUM and share price |
Posted at 10/1/2024 13:49 by petroc Welcome to the world of FUM, Phatty! The share price never does what you expect it to! |
Posted at 13/10/2023 18:06 by mdi The first RNS regarding the Co High Chinese collaboration was 4/3/2021. The shares traded through 36p on 19/3/2021 on still unexplained very high volumes of over 36m shares trading on that day alone in March 2021. So the share price is back to where it was in March 2021 and anyone who bought in the market above the current share price of 36p over the last two and half years has lost money on those shares. The Co High exercising their warrants RNS was 1/4/2021 at 22p and the conversion of the Chinese collaboration convertible loan notes into 7.5m FUM shares at 20p was 15/4/2023. So Co High can keep selling those 20p shares into the market. Just like the Directors and employees who recently got 20p options can sell them all the way back down to 20p and still be in the money. With the small retail investors having to average down and be left sitting on more losses. While Co High and FUM Directors/employees continue to be able to sell out their millions of 20p shares making money at their expense until Haleon makes its announcement in ‘due course’ on the ‘ongoing regulatory development’ requirement for USA. Unlike with what happened with Co High and the exact reasons for why Eroxon failed to progress in China. Haleon is a public company so the detail and outcome of any ‘pivotal study’ ie double blind placebo controlled on Eroxon will eventually be made public.‘Haleon is responsible for the future launch and ongoing regulatory, development, marketing, and commercialization of MED3000 in the USA. Further details will be disclosed in due course’ |
Posted at 13/10/2023 17:09 by mdi If you go back to the RNS dated 4/3/2021. Guess what the share price was around that day. 36p. So FUM are back to the share price obtained two and a half years ago. Co High got just under 9m shares for 20p but since then there was some unexplained collapse of this Chinese agreement with FUM. Many now saying its High Co who has been selling their remaining shareholding. Did the Chinese require the same ‘pivotal study’ as required by the FTC ie a pivotal double blind placebo controlled?‘This is expected to include a pivotal study in order to gain OTC regulatory approval within China’ Is that why Co High are selling out before it’s announced about the Haleon study that also is now required? ‘China and South East Asia - Termination of commercial agreement In March 2021 Futura announced a Joint Collaboration with Co-High for the regulatory development, approval and commercialisation of MED3000 in South East Asia. Unfortunately, this collaboration has not progressed as Futura had hoped’ |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
